jurnalul român de psihofarmacologie romanian journal of ...
jurnalul român de psihofarmacologie romanian journal of ...
jurnalul român de psihofarmacologie romanian journal of ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
54. Smeraldy E. Amisulpri<strong>de</strong> versus fluoxetine in patients with dysthymia or major <strong>de</strong>pression<br />
in partial remission: a double-blind, comparative study. J Affect Disord 1998; 48:47-56.<br />
55. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpri<strong>de</strong> versus amineptine and<br />
placebo for the treatment <strong>of</strong> dysthymia. Neuropsychobiology 1999; 39:25-32.<br />
56. Amore M, Jori MC. Faster response on amisulpri<strong>de</strong> 50 mg versus sertraline 50-100 mg in<br />
patients with dysthymia or double <strong>de</strong>pression: a randomized, double-blind, parallel group<br />
study. Int Clin Psychopharmacol 2001; 16:317-324.<br />
57. Cassano GB, Jori MC. Efficacy and safety <strong>of</strong> amisulpri<strong>de</strong> 50 mg versus paroxetine 20 mg<br />
in major <strong>de</strong>pression: a randomized, double-blind parallel group study. Int Clin<br />
Psychopharmacol 2002; 17:27-32.<br />
58. Dollfus S, Petit M, Menard JF, Lesieur P. Amisulpri<strong>de</strong> versus bromocriptine in infantile<br />
autism: a controlled crossover comparative study <strong>of</strong> two drugs with opposite effects on<br />
dopaminergic function. J Autism Def Desord 1992; 22:47-60.<br />
59. Wetzel H, Wiesner J, Hiemke C, Benkert O. Acute antagonism <strong>of</strong> dopamine D2-like<br />
receptors by amisulpri<strong>de</strong>: effects on hormone secretion in healthy volunteers. J Psychiatr<br />
Res 1994; 28:461-673.<br />
60. Gruen<strong>de</strong>r G, Wetzel H, Schloser R, Anghelescu I, Hillert A, Lange K, Hiemke C, Benkert<br />
O. Neuroendocrine response to antipsychotics: effect <strong>of</strong> drug type and gen<strong>de</strong>r. Biol<br />
Psychiatry 1999; 45:89-97.<br />
61. Coulovrat C, Don<strong>de</strong>y-Nouvel L, Blanchet S. Safety <strong>of</strong> amisulpri<strong>de</strong> (solian). A review <strong>of</strong> 11<br />
clinical studies. Int Clin Psychopharmacol 1999; 14:209-218.<br />
62. Lambert M, Naber N. Amisulprid – ein atypisches Antipsychotikom in <strong>de</strong>r Behandlung<br />
schizophrener Erkrankungen. Fundamenta Psychiatrica 1999; 13:43-61.<br />
63. Scatton B, Claustre Y, Cu<strong>de</strong>nnec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H.<br />
Amisulpri<strong>de</strong>: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol<br />
1997; 12(suppl. 2):29-36.<br />
64. Coukell AJ, Spencer CM, Benfield P. Amisulpri<strong>de</strong>. A review <strong>of</strong> its pharmacodynamic and<br />
pharmacokinetic properties and therapeutic efficacy in the management <strong>of</strong> schizophrenia.<br />
CNS Drugs 1996; 6:237-256.<br />
65. Wagstaff AJ, Bryson HM. Clozapine. A review <strong>of</strong> its pharmacological properties and<br />
therapeutic use in patients with schizophrenia who are unresponsive to or intolerant <strong>of</strong><br />
classical antipsychotic agents. CNS Drugs 1995; 4:370-400.<br />
66. Ashby TR Jr, Wang RY. Pharmacological actions <strong>of</strong> the atypical antipsychotic drug<br />
clozapine: a review. Syinapse 1996; 24:349-394.<br />
137
Change language